Can Intricate Modus Operandi of Interferons in Viral Diseases Bring Real Hope in COVID-19 Pandemic Situation?
Interferons (IFN), a family of naturally occurring proteins, are secreted mainly from White Blood Cells (WBC), Natural killer cells, fibroblasts and epithelial cells. They are the primary modulator of response of the immune system to viruses, bacteria, cancer and other foreign substances that inva...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
JCDR Research and Publications Private Limited
2020-10-01
|
Series: | Journal of Clinical and Diagnostic Research |
Subjects: | |
Online Access: | https://jcdr.net/articles/PDF/14096/45526_CE[Ra1]_F(SL)_PF1(AB_SL)_PFA(SL)_PN(SL).pdf |
Summary: | Interferons (IFN), a family of naturally occurring proteins, are secreted mainly from White Blood Cells (WBC), Natural killer cells,
fibroblasts and epithelial cells. They are the primary modulator of response of the immune system to viruses, bacteria, cancer and
other foreign substances that invade the body. Three types of IFNs have been identified till date and commercially available now
by recombinant DNA technology. Type 1 IFN especially IFN-β has already successfully passed the clinical trial against Middle East
Respiratory Syndrome related Corona Virus (MERS-CoV) and also being tried in “Solidarity clinical trial for COVID-19 treatments”
announced by World Health Organisation (WHO) in March, 2020. Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
emerged from China in December, 2019. It has rapidly spread out all over the world and become pandemic now. It has infected more
than eight million and killing around four lac people worldwide up to June 17, 2020. Elderly persons and people with comorbidities
like diabetes, chronic lung diseases, cardiovascular diseases and immune compromised states are the primary victim of this deadly
virus. In this regard, we are trying to evaluate the potential benefits of type 1 IFN as a promising and safer treatment modality as
well as specific prognostic marker when there are no specific and established vaccines, drugs or prognostic biomarkers available
yet against SARS-CoV-2. We can hypothesise that thorough evaluation of these molecules against COVID-19 may open-up a new
opportunity to successfully combat this evil. |
---|---|
ISSN: | 2249-782X 0973-709X |